Alto Neuroscience (NYSE:ANRO) Stock Rating Reaffirmed by Stifel Nicolaus

Stifel Nicolaus reiterated their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $32.00 price target on the stock.

ANRO has been the subject of a number of other reports. Robert W. Baird initiated coverage on Alto Neuroscience in a research note on Tuesday, February 27th. They set an outperform rating and a $32.00 target price for the company. Jefferies Financial Group initiated coverage on Alto Neuroscience in a research report on Tuesday, February 27th. They set a buy rating and a $33.00 price target for the company. William Blair initiated coverage on Alto Neuroscience in a research report on Tuesday, February 27th. They set an outperform rating for the company. Finally, TD Cowen initiated coverage on Alto Neuroscience in a research report on Tuesday, February 27th. They set an outperform rating for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Alto Neuroscience presently has a consensus rating of Buy and an average target price of $32.33.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $16.78 on Monday. Alto Neuroscience has a one year low of $12.83 and a one year high of $24.00.

Insiders Place Their Bets

In other news, major shareholder Wave Global Lp Alpha acquired 600,000 shares of the stock in a transaction on Tuesday, February 6th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $9,600,000.00. Following the transaction, the insider now directly owns 3,707,757 shares of the company’s stock, valued at $59,324,112. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.